文献速递乳腺癌放疗

老年I期ER阳性乳腺癌单纯放疗未增加第二乳腺癌事件风险

Radiation Without Endocrine Therapy in Older Women With Stage I Estrogen-Receptor-Positive Breast Cancer is Not Associated With a Higher Risk of Second Breast Cancer Events.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-05-08

PURPOSE: The omission of radiation therapy (RT) in older women with stage 1 estrogen-receptor-positive (ER+) breast cancer receiving endocrine therapy (ET) is an acceptable strategy based on randomized trial data. Less is known about the omission of ET with or without RT.…

要点

  • 单纯放疗未增加第二乳腺癌事件风险
  • 单纯内分泌和未治疗均增加第二乳腺癌事件风险
  • HER2阳性和pT1c与第二乳腺癌事件风险升高相关

核心结论

  • 老年I期ER阳性乳腺癌保乳术后单纯放疗与内分泌联合放疗相比第二乳腺癌事件风险无显著差异。

主要发现

  • 44%患者接受内分泌联合放疗,41%单纯放疗,6.6%单纯内分泌,8.6%两者均无。

关键数值与推荐

  • 80至85岁患者相比66至69岁患者更可能接受两者均无(OR 8.9)、单纯放疗(OR 1.9)或单纯内分泌(OR 8.8)。

临床怎么用

  • 老年I期ER阳性乳腺癌患者保乳术后可考虑单纯放疗而不必担心增加第二乳腺癌事件风险。
  • 省略内分泌治疗需谨慎,因单纯内分泌和未治疗均与更高的第二乳腺癌事件风险相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The omission of radiation therapy (RT) in older women with stage 1 estrogen-receptor-positive (ER+) breast cancer receiving endocrine therapy (ET) is an acceptable strategy based on randomized trial data. Less is known about the omission of ET with or without RT. METHODS AND MATERIALS: We analyzed surveillance, epidemiology, and end results (SEER)-Medicare data for 13,321 women age 66 years or older with stage I ER+ breast cancer from 2007 to 2012 who underwent breast-conserving surgery. Patients were classified into 4 groups: (1) ET + RT (reference); (2) ET alone; (3) RT alone; and (4) neither RT nor ET (NT). Second breast cancer events (SBCEs) were captured using the Chubak high-specificity algorithm. We used χ2 tests for descriptive statistics, multivariable multinomial logistic regression to estimate relative risk of undergoing a treatment, and multivariable, propensity-weighted competing-risks survival regression to estimate standardized hazard ratio (SHR) of SBCE. We set significance at P ≤ .01. RESULTS: Most women underwent both treatments, with 44% undergoing ET + RT, 41% RT alone, 6.6% ET alone, and 8.6% NT, but practice patterns varied over time. From 2007 to 2012, RT decreased from 49% to 30%, whereas ET alone and ET + RT increased (ET alone, 5.4%-9.6%; ET + RT, 38%-51%). Compared with patients age 66 to 69 years, patients age 80 to 85 years were more likely to receive NT (odds ratio [OR], 8.9), RT (OR, 1.9), or ET (OR, 8.8) versus ET + RT (P < .01). Three percent of subjects had an SBCE (2.2% ET + RT, 3.0% RT alone, 3.2% ET alone, 7.0% NT). Relative to ET + RT, NT and ET alone were associated with higher SBCE (NT: SHR, 3.7, P < .001; ET alone: SHR, 2.2, P = .008), whereas RT was not associated with a higher SBCE (SHR 1.21; P = .137). Clinical factors associated with higher SBCE were HER2 positivity and pT1c (SHR, 1.7; P = .006). CONCLUSIONS: Treatment with RT alone in older women with stage I ER+ disease is decreasing. RT alone is not associated with an increased risk for SBCE. By contrast, NT and ET are both associated with higher SBCE in multivariable analysis with propensity weighting. Further study of the omission of endocrine therapy in this patient population is warranted.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Gerber NK, Shao H, Chadha M, et al. Radiation Without Endocrine Therapy in Older Women With Stage I Estrogen-Receptor-Positive Breast Cancer is Not Associated With a Higher Risk of Second Breast Cancer Events. Int J Radiat Oncol Biol Phys. 2021. PMID: 33974886. doi:10.1016/j.ijrobp.2021.04.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。